Shares of AlloVir, Inc. (NASDAQ:ALVR – Get Free Report) traded down 1.1% during mid-day trading on Tuesday . The stock traded as low as $6.46 and last traded at $6.50. 41,026 shares traded hands during trading, an increase of 162% from the average session volume of 15,685 shares. The stock had previously closed at $6.57.
AlloVir Stock Performance
The company has a market cap of $30.84 million, a P/E ratio of -0.30 and a beta of 0.63. The stock has a 50 day moving average price of $9.26 and a 200 day moving average price of $7.35.
AlloVir Company Profile
AlloVir, Inc is a clinical-stage biopharmaceutical company specializing in the development of off-the-shelf, allogeneic virus-specific T-cell immunotherapies for the prevention and treatment of life-threatening viral infections in immunocompromised patients. The company’s proprietary Multi-Virus-Targeting Cell (MTC) platform enables the rapid identification, isolation and expansion of virus-specific T cells from healthy donors, with the aim of offering broad coverage against multiple clinically significant viruses.
AlloVir’s pipeline includes several product candidates designed to address unmet needs in transplant medicine and other immunosuppressed settings.
Recommended Stories
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.
